- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Profusa Lags Behind Competitors in Key Metrics
Analysis shows Profusa underperforms industry peers across various financial and operational measures.
Published on Mar. 11, 2026
Got story updates? Submit your updates here. ›
A critical analysis of Profusa (NASDAQ:PFSA), a publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry, reveals that it lags behind its competitors on several key metrics. The company has lower institutional and insider ownership, more volatile share price, weaker consensus analyst ratings, and poorer financial performance compared to its peers in the industry.
Why it matters
As an investor, understanding how a company compares to its industry competitors is crucial in evaluating its long-term growth potential and investment worthiness. The analysis highlights areas where Profusa is underperforming, which could impact shareholder value and the company's competitive positioning.
The details
The data shows that only 9.8% of Profusa's shares are held by institutional investors, compared to 19.3% for the industry overall. Insider ownership is also lower at 11.4% versus 19.9% for competitors. Profusa has a beta of 0.01, indicating its share price is 99% less volatile than the S&P 500, while its peers have an average beta of 1.80. Analysts also have a stronger consensus rating and see higher potential upside for Profusa's competitors. In terms of profitability, Profusa lags behind its peers on net margins, return on equity, and return on assets.
- The analysis is based on data reported as of March 11, 2026.
The players
Profusa
A publicly-traded company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry.
NorthView Acquisition Corporation
A subsidiary of NorthView Sponsor I, LLC that intends to focus its search on businesses in the healthcare sector.
The takeaway
Profusa's underperformance across key metrics compared to its industry peers raises concerns about the company's long-term competitiveness and growth potential. Investors should closely monitor Profusa's ability to address these gaps and improve its financial and operational performance to remain an attractive investment option.
